FIELD: organic chemistry of heterocyclic compounds, medicine, pharmacy. SUBSTANCE: invention relates to a novel 2-4-[4-(4,5-dichloro-2-methylimidazole-1-yl)butyl] -1-piperazinyl-5-fluoropyrimidine of the formula (I) 
and to its physiologically acceptable salts, for example, citrate, methods of their synthesis and a pharmaceutical composition. The compound of the formula (I) is synthesized by reaction of 8-(5-fluoro-2-pyrimidinyl)-8- aza-5-azoniaspiro-[4,5]-decane with 4-dichloro-2-methyl-1H-imidazole in the presence of potassium carbonate in medium of a polar solvent, for example, dimethylformamide at a boiling point of reaction from 70 C to a solvent boiling point for 3-48 h; or by reaction of 5-fluoro-2-(piperazine-1-yl)-pyrimidine with 1-(4-chlorobutyl-4,5-dichloro- 2-methyl-1H-imidazole under the above indicated conditions or under conditions of the phase transition using an aqueous solution of sodium hydroxide, toluene and a catalyst, for example, tetrabutylammonium bromide at temperature from 50 C to 90 C for from 12 to 72 h. The proposed pharmaceutical composition comprises a compound of the formula (I), its physiologically acceptable salts and a pharmaceutically acceptable base. Compounds of the formula (I) can be used for preparing a medicinal agent designated for treatment of vertigo, transport sick (nausea), depression, troubling state, acid secretion in stomach, obsessive or compulsive disorders, panic attacks and apnea during sleep. EFFECT: new compound indicated above, improved method of synthesis, valuable medicinal properties. 7 cl, 6 ex
